Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paragon CareASX:PGC +3.70%53 Debt-to-Equity is 1.31 as of Dec. 2025, which is 111% above its 10-year median of 0.62. GuruFocus rates ASX:PGC with a GF Score™ of 53/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 99 Medical Distribution companies, Paragon Care ranks worse than 83.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Paragon Care's Debt-to-Equity or its related term are showing as below:
ASX:PGC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.45 Med: 0.62 Max: 1.49
Current: 1.31
During the past 13 years, the highest Debt-to-Equity Ratio of Paragon Care was 1.49. The lowest was 0.45. And the median was 0.62.
ASX:PGC's Debt-to-Equity is ranked worse than 83.84% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs ASX:PGC: 1.31
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Paragon Care Debt-to-Equity Related Terms
Paragon Care Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Paragon Care's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PGC vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Paragon Care's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paragon Care Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Paragon Care's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Paragon Care's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paragon Care (ASX:PGC) has a Debt-to-Equity of 1.31 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paragon Care and its competitors. This is 111% above median its historical median of 0.62. Over the past decade, Paragon Care's Debt-to-Equity has ranged from 0.45 to 1.49. According to the industry distribution chart, Paragon Care ranks #83 out of 99 companies in the Medical Distribution industry, placing it in the top 83.8%.
Is Paragon Care's Debt-to-Equity too high?
Paragon Care's current Debt-to-Equity of 1.31 is 111% above median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 1.49. The Medical Distribution industry median Debt-to-Equity is 0.48. Paragon Care's value of 1.31 is 172.9% above this industry median. Based on the distribution chart, Paragon Care ranks #83 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Paragon Care has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Paragon Care ranks #83 out of 99 companies for Debt-to-Equity. This places Paragon Care in the lower half of its industry. The industry median Debt-to-Equity is 0.48. Paragon Care's value of 1.31 is 172.9% above this benchmark. Historically, Paragon Care's own Debt-to-Equity has ranged from 0.45 to 1.49 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.48, Paragon Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paragon Care's current Debt-to-Equity of 1.31 is 172.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Paragon Care and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paragon Care's current Debt-to-Equity is 1.31, which is 111% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (ASX:PGC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.14 — trading 65% below its estimated fair value. The current Debt-to-Equity is 1.31, which is 111% above median its 10-year median of 0.62 and 172.9% above the Medical Distribution industry median of 0.48. Paragon Care's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Paragon Care (ASX:PGC), the current Debt-to-Equity is 1.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paragon Care (ASX:PGC) Overvalued in 2026?
Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued.
The current stock price of A$0.14 is trading 65% below its estimated GF Value™ of A$0.40.
GuruFocus considers Paragon Care to be Possible Value Trap.
Key valuation signals for ASX:PGC:
Debt-to-Equity: 1.31 (111% above median its 10-year median of 0.62)
GF Value™: A$0.40 vs. price of A$0.14 (65% below fair value)
Industry Position: 172.9% above the Medical Distribution median (#83 of 99)
No single metric tells the full story. See the ASX:PGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
53GF Score
Get the complete analysis for ASX:PGC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PGC has been successfully added to your 
